Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00515086 · ClinicalTrials.gov registry record · Phase 2
Study of Everolimus (RAD001) in Patients With Recurrent Glioblastoma Multiforme (GBM)
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT00515086 is a Phase 2 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 41 participants.
The verdict
NCT00515086, a Phase 2 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
This study will define the safety and efficacy of Everolimus (RAD001) administered daily in patients with glioblastoma multiforme (GBM)
Interventions
- DRUG Everolimus
- PROCEDURE Surgery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2007-08 |
| Est. Completion | 2009-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00515086
The ClinicalTrials.gov registry entry for NCT00515086 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Everolimus is the first listed.
NCT00515086 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00515086 about?
NCT00515086 is a clinical study titled "Study of Everolimus (RAD001) in Patients With Recurrent Glioblastoma Multiforme (GBM)". This study will define the safety and efficacy of Everolimus (RAD001) administered daily in patients with glioblastoma multiforme (GBM)
What is the current status of trial NCT00515086?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2007-08. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00515086?
The interventions under investigation include: Everolimus (DRUG), Surgery (PROCEDURE).
Who is sponsoring clinical trial NCT00515086?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.